Current issues in the management of secondary hyperparathyroidism and bone disease

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Recent research has demonstrated active bone-like remodelling of vascular tissue in dialysis and non dialysis patients. Cross-sectional studies indicate that the presence of vascular calcification is inversely related to bone mass. Theoretically, the relationship implies that maintaining normal bone turnover and mass may help to decrease vascular calcification. In addition, it is now apparent that phosphorus and the Ca × P product need to be kept as close to normal as possible. Thus, the present goal should be a serum phosphorus of 3.5 - 5.5 mg/dL, a Ca × P product of <55 mg/dL, and a PTH of around 150 - 200 pg/mL with the intact assay. Ten years ago, those goals would have been impossible. However, new pharmacologic agents will make their achievement much more realistic.

Original languageEnglish
JournalPeritoneal Dialysis International
Volume21
Issue numberSUPPL. 3
StatePublished - 2001

Fingerprint

Vascular Calcification
Secondary Hyperparathyroidism
Bone Remodeling
Bone Diseases
Phosphorus
Dialysis
Blood Vessels
Cross-Sectional Studies
Bone and Bones
Serum
Research

Keywords

  • Adynamic bone disease
  • Renal osteodystrophy
  • Secondary hyperparathyroidism

ASJC Scopus subject areas

  • Nephrology

Cite this

Current issues in the management of secondary hyperparathyroidism and bone disease. / Moe, Sharon.

In: Peritoneal Dialysis International, Vol. 21, No. SUPPL. 3, 2001.

Research output: Contribution to journalArticle

@article{4fdb9e8ae23945bd88c71b71ca38bcf5,
title = "Current issues in the management of secondary hyperparathyroidism and bone disease",
abstract = "Recent research has demonstrated active bone-like remodelling of vascular tissue in dialysis and non dialysis patients. Cross-sectional studies indicate that the presence of vascular calcification is inversely related to bone mass. Theoretically, the relationship implies that maintaining normal bone turnover and mass may help to decrease vascular calcification. In addition, it is now apparent that phosphorus and the Ca × P product need to be kept as close to normal as possible. Thus, the present goal should be a serum phosphorus of 3.5 - 5.5 mg/dL, a Ca × P product of <55 mg/dL, and a PTH of around 150 - 200 pg/mL with the intact assay. Ten years ago, those goals would have been impossible. However, new pharmacologic agents will make their achievement much more realistic.",
keywords = "Adynamic bone disease, Renal osteodystrophy, Secondary hyperparathyroidism",
author = "Sharon Moe",
year = "2001",
language = "English",
volume = "21",
journal = "Peritoneal Dialysis International",
issn = "0896-8608",
publisher = "Multimed Inc.",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Current issues in the management of secondary hyperparathyroidism and bone disease

AU - Moe, Sharon

PY - 2001

Y1 - 2001

N2 - Recent research has demonstrated active bone-like remodelling of vascular tissue in dialysis and non dialysis patients. Cross-sectional studies indicate that the presence of vascular calcification is inversely related to bone mass. Theoretically, the relationship implies that maintaining normal bone turnover and mass may help to decrease vascular calcification. In addition, it is now apparent that phosphorus and the Ca × P product need to be kept as close to normal as possible. Thus, the present goal should be a serum phosphorus of 3.5 - 5.5 mg/dL, a Ca × P product of <55 mg/dL, and a PTH of around 150 - 200 pg/mL with the intact assay. Ten years ago, those goals would have been impossible. However, new pharmacologic agents will make their achievement much more realistic.

AB - Recent research has demonstrated active bone-like remodelling of vascular tissue in dialysis and non dialysis patients. Cross-sectional studies indicate that the presence of vascular calcification is inversely related to bone mass. Theoretically, the relationship implies that maintaining normal bone turnover and mass may help to decrease vascular calcification. In addition, it is now apparent that phosphorus and the Ca × P product need to be kept as close to normal as possible. Thus, the present goal should be a serum phosphorus of 3.5 - 5.5 mg/dL, a Ca × P product of <55 mg/dL, and a PTH of around 150 - 200 pg/mL with the intact assay. Ten years ago, those goals would have been impossible. However, new pharmacologic agents will make their achievement much more realistic.

KW - Adynamic bone disease

KW - Renal osteodystrophy

KW - Secondary hyperparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=0035568839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035568839&partnerID=8YFLogxK

M3 - Article

C2 - 11887830

AN - SCOPUS:0035568839

VL - 21

JO - Peritoneal Dialysis International

JF - Peritoneal Dialysis International

SN - 0896-8608

IS - SUPPL. 3

ER -